CANF vs ITOS

Can-Fite Biopharma Ltd

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, COVID-19 and erectile dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah-Tikva, Israel.

iTeos Therapeutics Inc.

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.